To navigate the intricate challenges that define #CGT distribution, a forward-thinking approach is foundational to achieving commercial success. In an interview with Pharm Exec, Cencora’s Melissa Lattanzi, Vice President, Emerging Therapies, delves into crucial considerations that cell and gene therapy (CGT) developers must address to shape an effective distribution strategy ⬇️ https://ow.ly/GuyI50SEvb1
Cencora | Pharma solutions’ Post
More Relevant Posts
-
Strategic Leadership | Healthcare Executive | Business Development | Cross-functional Collaboration | Operations Management
A coordinated orchestration with tailored services, distribution and advanced analytics is critical to unlocking value for our CGT partners.
To navigate the intricate challenges that define #CGT distribution, a forward-thinking approach is foundational to achieving commercial success. In an interview with Pharm Exec, Cencora’s Melissa Lattanzi, Vice President, Emerging Therapies, delves into crucial considerations that cell and gene therapy (CGT) developers must address to shape an effective distribution strategy ⬇️ https://ow.ly/GuyI50SEvb1
-
-
Have you read our recently released target product profile (TPP) guide and want to learn more about how to develop an effective TPP for successful therapy adoption? Join our webinar on the 31st of January titled 'Developing a robust target product profile (TPP) for successful therapy adoption', where Cell and Gene Therapy Catapult’s experts in #MarketAccess, #RegulatoryAffairs and #NonClinical strategy will talk through the guide, discuss the value of a TPP and how to approach building one. Register now: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #TherapyDevelopers
-
-
New on Pharma's Almanac: PPD’s Erin Schaller and Aidan Jones discuss how the growth of cell and gene therapies have produced a myriad of logistical supply chain challenges around management of complex samples, making an experienced and expert clinical research partner more critical than ever. Read the article here: https://lnkd.in/erFU493y #clinicaltrials #clinicalsupply #logistics #celltherapy #cellandgenetherapy #clinicaltriallogistics #supplychain
-
-
In an industry where change is ever constant, Andelyn Biosciences stands as your steadfast partner in gene therapy manufacturing. With over two decades of experience and expertise, our commitment to growth and innovation ensures we're here for you, ready to bring your groundbreaking therapies from the lab to the patient. See what a feasibility study and yield assessment can do to get your program started on a path to process industrialization: https://buff.ly/3UzqzNP #andelynbiosciences
-
-
Interested in learning how the #AdvancedTherapies industry can enhance today's manufacturing practices to establish fully automated, digitally integrated processes? ➡️ https://buff.ly/3BthKPL Daniel Gibson, Head of Collaborations at the Cell and Gene Therapy Catapult, highlights this and more in his key takeaways from Phacilitate's recent Advanced Therapies Europe event. Read the blog ☝️ #CellTherapy #GeneTherapy #ATMPs
-
-
Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C>) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C> field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24
-
-
Mark your calendars for Navitus' Drug Pipeline Insights Webinar to learn more about how upcoming drug releases may affect your clients and their benefit designs. Register today: https://lnkd.in/gY7FmA7c #biosimilars #employeebenefits #pbm #healthcare #pharmacybenefits
Planned biosimilar, generic and gene therapy releases may affect your clients and their benefit designs – join our upcoming webinar for insights that best prepare you to help drive decisions. Alex Peaslee, PharmD, will frame the current approval environment and discuss the 2024-25 pipeline outlook. Register today: https://ow.ly/8XtQ50SL6oa
-
-
#Whitepaper: As the field of Cell & Gene Therapy rapidly advances, there has been a corresponding growth in supply chain solutions to meet the precise requirements of this industry. Our newest #BioServices Whitepaper discusses the growing demand for supply chain management and compliance standards needed for managing cell and gene materials. $CYRX Read The Whitepaper: https://cyrx.co/4cFFaQ4
-
-
Are you a drug developer and want to know how to increase the likelihood of successful clinical adoption of your advanced therapy? Register at the link below and hear from my colleagues at the Non-clinical, Regulatory Affairs, and HEMA teams at Cell and Gene Therapy Catapult to improve your understanding of the target product profile (TPP) for a more effective translation of your product. #clinicaladoption #catapult #CGTC #nonclinical #HEMA #regulatoryaffairs #TPP
One week to go until the experts in market access, regulatory affairs, and non-clinical strategy at the Cell and Gene Therapy Catapult will be delivering a webinar on 'Developing a robust target product profile (TPP) for successful therapy adoption'. If you are looking to improve your understanding of the characteristics of a TPP, attending this webinar is essential to learn how to create your own robust #TPP and increase the likelihood of successful adoption of your #AdvancedTherapy. Learn more: https://buff.ly/3RqT2nC ##TPP #CGTDeveloper #CellTherapies #GeneTherapies
-
-
#Whitepaper: As the field of Cell & Gene Therapy rapidly advances, there has been a corresponding need for supply chain solutions to meet the precise requirements of this industry. Our newest BioServices Whitepaper discusses the growing demand for supply chain management and compliance standards needed for managing cell and gene materials. $CYRX Read The Whitepaper: https://cyrx.co/4cFFaQ4 #BioServices
-
